Skip to main content

Table 2 Mean pain intensity over the previous 24 hours at each study visit (per-protocol population; non-last observation carried forward analysis)

From: Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials

Name (visit)

Pain Intensity Scale score

  

Oxycodone PR

Oxycodone/Naloxone PR

Total

Randomisation

(Visit 3)

N

208

221

429

 

Mean (SD)

3.3 (0.97)

3.4 (1.07)

3.4 (1.02)

 

Median

3.0

3.0

3.0

 

Min, Max

0.0, 7.0

0.0, 9.0

0.0, 9.0

Week 1

(Visit 4)

N

208

220

428

 

Mean (SD)

3.5 (1.3)

3.6 (1.51)

3.6 (1.41)

 

Median

3.0

4.0

4.0

 

Min, Max

0.0, 7.0

0.0, 9.0

0.0, 9.0

Week 4

(Visit 6)

N

208

220

428

 

Mean (SD)

3.5 (1.37)

3.5 (1.51)

3.5 (1.44)

 

Median

3.0

4.0

3.5

 

Min, Max

0.0, 7.0

0.0, 9.0

0.0, 9.0

Week 12

(Visit 8)

N

204

220

424

 

Mean (SD)

3.5 (1.53)

3.6 (1.78)

3.6 (1.67)

 

Median

4.0

4.0

4.0

 

Min, Max

0.0, 8.0

0.0, 9.0

0.0, 9.0

  1. Min = minimum; Max = maximum; PR = prolonged-release; SD = standard deviation